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Stem cell–based therapeutic modalities are in-
creasingly considered for organ repair (1–5). 
Current clinical trials use adult stem cells, ad-
dressing their safety and effi   cacy (6–9). While 
optimization of adult cytotypes is ongoing 
(10, 11), recognition of the vigorous regenerative 
capacity of embryonic stem cells has created a 
distinct opportunity in cardiovascular medicine 
(12–16). Isolated from the inner cell mass of 
blastocysts, embryonic stem cells have a unique 
aptitude to form ectoderm, mesoderm, and en-
doderm (17), revealing this population as a re-
newable cell source with a reliable potential 
for cardiogenesis (18–22). However, use of 
embryonic stem cells carries a latent threat for 
neoplastic transformation caused by the inher-
ent propensity associated with pluripotency for 
unguided diff  erentiation upon transplantation 
(23–25). This risk particularly transpires when 
embryonic stem cells are removed from the 
  inner cell mass of a diff  erentiating blastocyst 
and established in vitro before implantation in 
a foster environment, such as that of the host 
myocardium (26).
During embryogenesis, as embryonic stem 
cells diff  erentiate into the three germinal lay-
ers, markers of pluripotency decline with tissue 
specifi  cation (27). Cardiac diff  erentiation in the 
embryo proceeds within the anterolateral me-
soderm and requires the instructive guidance 
of the adjacent endoderm (28–30). Cardio-
genic instruction induces expression of the 
  homeobox gene Nkx2.5, the earliest molecular 
marker of the cardiac fate (31). Nkx2.5 then 
activates transcription of the myocyte enhancer 
factor MEF-2C to promote cardiomyocyte dif-
ferentiation and cooperates with zinc fi  nger 
transcription factors of the GATA family to ini-
tiate cardiac gene expression (32, 33). Though 
the heart can mimic the endoderm in guiding 
stem cell cardiogenesis, its capacity to secure 
cardiogenic transformation is limited compared 
with the embryo itself (34), creating a threat for 
unguided growth that impedes safe embryonic 
stem cell use.
Here, the aptitude of recipient heart to pre-
vent unguided diff   erentiation of transplanted 
embryonic stem cells was enhanced through 
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transgenic expression of TNF-α, a reprogramming cytokine 
(35) and an integral component of the myocardial homeo-
static response (36). As the heart mimics the endoderm in 
guiding cardiogenesis, the embryoid body and isolated endo-
dermal cells were used to dissect TNF-α–mediated induction 
of cardiac diff  erentiation. The identity of TNF-α–induced 
proteins in the endodermal secretome was delineated through 
a subtractive proteomic approach. Combinatorial application 
of identifi  ed factors on a monolayer of embryonic stem cells 
was found to be suffi   cient in deriving a cardiac predeter-
mined progenitor population. Cardiopoietic programming 
eli  minated embryonic stem cell susceptibility for multilineage 
Figure 1.  Tumorigenic risk of embryonic stem cell therapy. 
(A–C) Transplantation of 3 × 105 embryonic stem cells into normal heart 
(A, transverse section) generated α-actinin–positive cyan fl  uorescent 
embryonic stem cell–derived cardiomyocytes (B and inset) that properly 
integrated into host myocardium (C). Bars: (A) 2 mm; (B) 70 μm; (B, inset 
and C) 10 μm. (D and E) Embryonic stem cells injected at 106–3 × 106 
cells per heart harbored a risk for uncontrolled growth with formation of 
teratoma that remained encapsulated (D and inset) or protruded into the 
thoracic cavity (E). Bars: (D and E) 2 mm; (D inset) 300 μm. (F) On histology 
with hematoxylin-eosin staining, diverse embryonic stem cell–derived 
phenotypes were documented. These included osteoblasts, chondrocytes, 
endothelial, epithelial, and germ cell types (fi  rst row), and adipocytes, 
keratinocytes, and myoblasts (third row), refl  ecting embryonic stem cell 
pluripotency. Immunohistochemistry was used to verify the multiplicity of 
cell types, i.e., using SOX9 to confi  rm chondrocytes and cytokeratin 7 for 
acinar epithelium (second row). Moreover, tumors derived from embryonic 
stem cells programmed to express GFP driven by the TIE2 promoter visu-
alized the endothelial phenotype (second row), whereas embryonic stem 
cells engineered to express CFP under the cardiac actin promoter revealed 
the presence of embryonic stem cell–derived cardiomyocytes within 
  teratomas (second and third row). Bars: F (all panels except epithelial in fi  rst 
row) 10 μm; (epithelial in fi  rst row) 5 μm; (CFP, inset) 100 μm.JEM VOL. 204, February 19, 2007  407
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  diff  erentiation averting the risk for tumorigenic outcome, 
  removing a critical impediment in therapeutic application.
RESULTS
Tumorigenic risk of embryonic stem cells transgenically 
manipulated in vivo
To assess the tumorigenic risk of pluripotent stem cells 
diff  erentiating outside of the natural embryonic program, 
embryonic stem cells were delivered at increasing loads into 
the myocardial parenchyma of wild-type mice. Delivery of 
embryonic stem cells at ≤1,000 cells/mg of myocardial tis-
sue ( 3 × 105 stem cells/heart) resulted in incorporation of 
stem cell–derived cardiomyocytes in the area of transplanta-
tion (n = 50 mice), tracked by fl  uorescence emitted upon 
cardiac diff  erentiation (Fig. 1, A and B). Autofl  uorescence 
and cell fusion were excluded through multiwavelength 
immunocytochemical and nuclear probing, indicating that 
embryonic stem cells undergo nonfusogenic cardiac trans-
formation in the recipient heart (Fig. 1 C). Transplantation 
of 3,000 embryonic stem cells/mg ( 106 stem cells/heart) 
resulted in teratoma formation within the myocardial pa-
renchyma in 18% of treated hearts (Fig. 1 D). Delivered 
at 10,000 per mg of myocardial mass ( 3  ×  106 stem 
cells/heart), embryonic stem cells escaped cardiogenic dif-
ferentiation in 68% of treated animals, generating massive 
tumors emanating from the heart into the thoracic cavity 
(Fig. 1 E). Embryonic stem cell–derived teratoma consisted 
of a multigerminal cellular heterogeneity, including osteo-
blasts, chondrocytes, adipocytes, keratinocytes, myoblasts, 
endothelial, epithelial tissue, and germinal cells (Fig. 1 F). 
Verifi  cation of cytotypes was made by immunostaining with 
SOX9 (chondrocytes) and cytokeratin7 (acinar epithelial 
cells) and through delivery of cells engineered to express 
cyan fl  uorescent protein (CFP) under control of the cardiac 
actin promoter (for cardiac cells) or GFP under control of 
the Tie2 promoter (for endothelial cells), revealing the nar-
row margin of safety associated with delivery of pluripotent 
stem cells in wild-type hearts (Fig. 1 F).
The propensity for tumorigenic outcome correlated with 
embryonic stem cell load (Fig. 2 A). The neoplastic threat 
associated with stem cell transplantation was eliminated by 
cardiac-restricted transgenic expression of the stress cytokine 
TNF-α (TNF-α–TG), averting tumorigenic outcome even 
at doses of 10,000 cells per mg of myocardial tissue ( 3 × 
106 stem cells/heart) that produced uncontrolled growth in 
wild-type hearts (Fig. 2 A). Up-regulated myocardial expres-
sion of TNF-α secured cardiac diff  erentiation of implanted 
embryonic stem cells with proper integration within host 
myocardium occurring over an increasing range of stem 
cell loads (Fig. 2, A and B). Autofl  uorescence and cell fu-
sion was ruled out by multiwavelength confocal visualization 
after immunohistochemical and nuclear probing (Fig. 2 C). 
The in vivo action of TNF-α was associated with myocardial 
up-regulation of the p38 mitogen-activated protein kinase 
and enhanced expression of the cardiogenic growth factor 
TGF-β (Fig. 2 D). Deletion of the TGF-β receptor kinase 
domain (∆TGF-βRII) in embryonic stem cells or disruption 
of the stem cell ability to recognize members of the TGF-β 
superfamily, i.e., BMP through overexpression of the BMP 
inhibitor, noggin, prevented cardiac diff  erentiation leading to 
Figure 2.  Neoplastic risk of embryonic stem cell therapy averted 
with transgenic cytokine overexpression. (A) Host heart (WT) demon-
strated a fi  nite capacity to secure tumor-free stem cell transplantation, 
i.e., 100% tumor-free outcome at 3 × 105 cells/heart versus 82% and 32% 
tumor-free outcomes at 106 cells/heart and 3 × 106 cells/heart, respec-
tively (blue). Transgenic cardiac-restricted overexpression of TNF-α (TNF-TG) 
increased the capacity of host heart to guide stem cell cardiogenesis 
  nullifying uncontrolled growth, i.e., 100% tumor-free outcome at 3 × 106 
cells/heart (red). Conversely, deletion of the kinase domain of the TGF-β 
receptor (∆TGFβRII) or overexpression of the BMP inhibitor Noggin, both 
disrupting cardiogenic signaling in embryonic stem cells (ES), precipitated 
tumorigenesis after transplantation, i.e., 0% tumor-free outcomes at 
3 × 105 cells/heart (light and dark green). For each condition, n indicates 
the number of treated animals. (B and C) TNF-α priming achieved tumor-
free incorporation of transplanted stem cells (3 × 106 cells/heart; top 
panel), with embryonic stem cell–derived cardiomyocytes integrating with 
host myocardium as determined by CFP expression (B, bottom and C). 
Bars: (B, top) 2 mm; (B, bottom and C) 10 μm. (D) Transgenic TNF-α over-
expression (TNFα-TG) up-regulated myocardial p38 MAPK and TGF-β 
expression with α-actinin used as a control for protein loading. (E and F) 
Blockade of the TGF-β superfamily through overexpression of Noggin or 
∆TGFβRII precipitated tumor formation because of uncontrolled growth 
of implanted embryonic stem cells even at 3 × 105 cells/heart.408  CARDIOPOIESIS FOR TUMOR-FREE REPAIR | Behfar et al.
Figure 3.  Procardiogenic TNF-𝗂 effects are mediated through the 
endoderm. (A) During embryoid body differentiation of embryonic stem 
cells (ES), mRNA expression profi  ling of cardiac transcription factors 
(Nkx2.5, MEF-2C, GATA4) revealed a window (days D4–D7) of exponential 
up-regulation (CARDIOPOIETIC WINDOW) 3 d before the appearance of 
sarcomeric mRNA (βMHC). Arbitrary units were calculated relative to the 
expression of β-tubulin used as denominator. (B and C) TNF-α (30 ng/ml) 
doubled the expression of cardiac transcription factors in comparison to 
untreated controls during the cardiopoietic window (B) and accelerated 
the formation of beating embryoid bodies (C). (D and E) TNF-α (30 ng/ml) 
increased sarcomeric content in treated ((+)TNFα) versus untreated 
((−)TNFα) embryoid bodies determined by α-actinin immunofl  uorescence 
at day 9 (D9) of differentiation (middle) without altering sarcomeric organ-
ization (right). Bars in D apply also to E. (F) The percentage of embryoid 
body area beating was dependent on the TNF-α concentration. (G) TNF-α 
treatment increased the yield of cardiomyocytes after isolation from 
  dissociated embryoid bodies. (H and I) The cardiogenic effect of TNF-α 
(30 ng/ml) on embryoid bodies was inhibited by infl  iximab (150 ng/ml), 
a neutralizing TNF-α antibody, as determined by beating area on video 
  microscopy (H) and α-actinin staining (I). (H, inset) TNF-α is effective only 
after the initiation of embryoid body differentiation (days 2–5) producing 
a 2.5-fold increase in cardiomyocyte yield compared with TNF-α–treated 
embryonic stem cells (day 0). (J) TNF-α required an intact endoderm to 
induce cardiogenesis, as endodermal disruption prevented cytokine action. 
Addition of conditioned medium from isolated ventral endoderm (Endo. 
Secretome) rescued cardiogenesis but did not restore the TNF-α effect. 
Addition of condition medium from TNF-α–treated endoderm (TNFα Rx 
Endo. Secr.) resulted in cardiogenesis at levels equal to that of TNF-α–
treated embryoid bodies irrespective of the presence of TNF-α on the 
embryoid body itself. *, P < 0.05 versus untreated.JEM VOL. 204, February 19, 2007  409
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tumor formation even at low stem cell loads (Fig. 2 A, E, 
and F). Thus, the tumorigenic risk of embryonic stem cells can 
be blunted by TNF-α cardiac-restricted overexpression or 
exaggerated by removal of the TGF-β superfamily guidance of 
transplanted cells.
Cardiogenic TNF-𝗂 action recapitulated in embryoid body 
requires endoderm
The procardiogenic action of TNF-α revealed through in 
vivo transgenesis was validated and dissected in vitro through 
diff  erentiation of embryonic stem cells in a controlled model 
of cardiogenesis (37). Within developing embryoid bodies, 
early cardiogenesis was characterized by a time window of 
exponential rise in markers of cardiac specifi  cation (Fig. 3 A). 
Between day 4 and 7 of diff  erentiation, genes encoding car-
diac transcription factors (Nkx2.5, MEF-2C, and GATA4) 
were reproducibly up-regulated before expression of sarco-
meric genes (β-MHC) indicative of terminal diff  erentiation 
(n = 6 diff  erentiation experiments with 20 embryoid bod-
ies for each time point; Fig. 3 A). Within this time win-
dow of early diff  erentiation, embryoid bodies treated with 
TNF-α (30 ng/ml) demonstrated signifi  cant up-regulation 
of Nkx2.5, MEF-2C, and GATA4 (n = 6 diff  erentiation 
experiments; Fig. 3 B) compared with untreated controls 
(P < 0.05). TNF-α treatment translated into an accelerated 
cardiac diff  erentiation determined by an earlier increase in 
the number of beating embryoid bodies sustained through-
out diff  erentiation  (n  = 80 embryoid bodies; Fig. 3 C). 
TNF-α, in a concentration-dependent manner, increased 
cardiac content within each embryoid body as determined at 
day 9 of diff  erentiation by α-actinin staining of sarcomeres 
(n = 30 embryoid bodies; Fig. 3, D and E), areas of beating 
activity (n = 30 embryoid bodies; Fig. 3 F), and quantifi  ca-
tion of cardiomyocyte yield (n = 3 diff  erentiation experi-
ments with 30 embryoid bodies for each isolation; Fig. 3 G). 
The cardiogenic eff  ect of TNF-α was prevented by cotreat-
ment with the TNF-α antagonist, infl  iximab (150 ng/ml, 
n = 6; Fig. 3, H and I). The action of TNF-α required that 
embryonic stem cells undergo trigerminal diff  erentiation into 
embryoid bodies as treatment of stem cells in the pluripotent 
state did not promote cardiogenesis (Fig. 3 I, inset). In fact, 
the cardiogenic eff  ect of TNF-α was found to be dependent 
on the endoderm (Fig. 3 J). Although trigerminal embryoid 
bodies displayed a vigorous response to TNF-α that aug-
mented the beating area by >2-fold above baseline (Fig. 3 J,
fi  rst pair), embryoid bodies lacking endoderm after treat-
ment with leukemia inhibitory factor (100 U/μl; 38) lost 
their cardiogenic response to TNF-α (Fig. 3 J, second pair). 
In endoderm-defi   cient embryoid bodies, rescue of base-
line cardiogenesis was achieved by addition of conditioned 
medium derived from isolated visceral endoderm-like cells 
(Fig. 3 J, third pair). Endoderm-defi  cient embryoid bodies 
rescued by visceral endoderm-conditioned medium did 
not, however, demonstrate a cardiogenic response to TNF-
α treatment,  indicating that the cytokine must target the 
endodermal layer (Fig. 3 J, third pair). Rescue of TNF-α 
action was achieved through treatment of endoderm-  defi  cient 
embryoid bodies with condition medium derived from 
TNF-α–primed visceral endoderm-like cells (Fig. 3 J, fourth 
pair). The boost in the cardiogenic propensity of endoderm-
derived conditioned medium after TNF-α stimulation was 
reproduced on pluripotent stem cells diff  erentiating in mono-
layer. Visceral endodermal-like cells treated with TNF-α had 
a twofold increased capacity to induce cardiogenic diff  eren-
tiation of embryonic stem cells, with the total yield of cells 
demonstrating nuclear translocation of Nkx2.5 and MEF-2C 
increased from 34 ± 4% in the untreated condition to 73 ± 
6% in the TNF-α–treated condition (data not shown). Thus, 
the procardiogenic action of TNF-α observed in vivo can be 
recapitulated in vitro with the action of the cytokine depen-
dent on the endoderm.
Endodermal response to TNF-𝗂 reveals 
cardiogenic candidates
Proteomic two-dimensional gel analysis revealed that the 
TNF-α stimulation of isolated visceral endoderm-like cells 
induced secretion of proteins involved in sarcomerogenesis 
(profi  lin and cofi  lin), calcium signaling (calcyclin), myocar-
dial reprogramming (nucleotide diphosphate kinase), and 
heart formation (FK506 binding protein FKBP12, cystatin, 
and ubiquitin) (39–42; Fig. 4 A). The identity of each protein 
was resolved by reconstruction of constitutive peptides using 
tandem mass spectrometry (Fig. 4 B) with the overall twofold 
increase in protein content after cytokine induction (Fig. 4 A, 
inset) confi   rmed at an individual protein level (Fig. 4 B, 
insets). Transcriptional profi  ling of total RNA revealed that 
970 genes changed >1.5-fold, of which 616 (64%) were 
up-regulated and 354 (36%) down-regulated in TNF-α–
stimulated compared with untreated visceral endoderm (Fig. 
4, C and D), underlying the cytokine induction of protein 
synthesis. Multidimensional liquid chromatography tandem 
mass spectrometric shotgun analysis, along with pathway 
analysis, was used to dissect the intracellular network down-
stream of TNF-α (Fig. 4 E), with protein identities estab-
lished from individual mass spectra (Fig. 4 F). Subtractive 
analysis of the genomic and proteomic data obtained from 
TNF-α–treated versus untreated endodermal secretome re-
solved several cytokine-induced secreted growth factors in-
cluding TGF-β1, bone morphogenetic protein (BMP)-1, -2, 
and -4, vascular endothelial growth factor (VEGF)-A, IL-6, 
epidermal growth factor (EGF), fi  broblast  growth  factor 
(FGF)-2 and -4, haploglobin, CSF-1, nerve growth factor 
(NGF)-β, and insulin-like growth factor (IGF)-1, and -2 (Fig. 
4 E). Unbiased network analysis of the identifi  ed nodes in the 
endoderm secretome using the Ingenuity Pathway Knowledge 
Base ranked the “cardiovascular system development” function 
as the most overrepresented subnetwork following TNF-α in-
duction, up from the twelfth rank in the untreated secretome 
and distanced by fi  vefold from the nearest function, identifying 
secreted factors as candidate cardiotrophs (Fig. 4 E).
Secreted factors IGF-1 and -2, CSF-1, BMP-1, and tissue 
inhibitor of metalloprotease-1 were initially resolved on 410  CARDIOPOIESIS FOR TUMOR-FREE REPAIR | Behfar et al.
Figure 4.  Proteomic and genomic dissection of TNF-𝗂–primed 
endodermal secretome. (A) Two-dimensional gel electrophoresis 
(at pH 3–10 and 6–11) was used to resolve the endodermal secretome 
concentrated from 5-ml aliquots, with examples of TNF-α up-regulated 
proteins circled. Protein content was increased approximately twofold in 
TNF-α–primed versus naive secretome (inset). Triangles: examples of 
down-regulated or unchanged proteins. (B) Example LTQ tandem mass 
spectrum showing FKBP-1A peptide (amino acids 2–14). This approach 
was used to resolve protein identities by respective constituent peptide 
sequence signatures of individual peptide mass spectra, with relative 
abundance quantifi  ed (inset left) based on spot density (inset right). 
(C) Transcriptional profi  ling of total RNA from TNF-α–treated and untreated 
endoderm showing differential gene expression, including examples of 
genes encoding proteins identifi  ed by proteomics. (D) Volcano plots 
  revealed that 64% of genes were up-regulated and 36% down-regulated 
in TNF-α–treated versus untreated endoderm. (E) Proteomic shotgun 
analysis of the TNF-α–treated endodermal secretome and ELISA revealed 
the identity of secreted proteins, including FGFs, leukemia inhibitory 
factor, VEGFs, TGF-βs, BMPs, CSF, IGFs, EGF, NGF, and ILs. Pathway analysis 
of identifi  ed proteins visualized the interactome triggered by cytokine 
stimulation and demonstrated secreted candidate cardiotrophic factors 
downstream of TNF-α integrated through p38-driven networks with 
individual proteins depicted in their corresponding cellular compart-
ments. Blue nodes refl  ect detection by proteomic analysis, and yellow 
nodes refl  ect ELISA confi  rmation. (F) Example of LTQ-FT shotgun tandem 
mass spectrum showing IGF-2 peptide (amino acids 74–89). This approach 
was used to provide a more sensitive means of detecting the presence 
of secreted proteins. *, P < 0.05.JEM VOL. 204, February 19, 2007  411
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shotgun proteomics, and expression was confi  rmed by gene 
array analysis (Fig. 5, A–D). TGF-β1 and BMP-4 were found 
up-regulated by twofold as demonstrated on ELISA (Fig. 5 E). 
Expression of BMP-2, VEGF-A, -B, and -C, IL- 6, EGF, 
and haploglobin was probed by gene array analysis and veri-
fi  ed by ELISA (Fig. 5 G). Expression profi  ling of endodermal 
mRNA after TNF-α treatment revealed up-regulation of 
TGF-β–activated kinase (TAK)-1 and TNF-α converting 
enzyme (TACE) (Adam17) by 1.5- and 2-fold, respectively 
(Fig. 5 F). Increase in TACE expression indicates NOTCH1-
dependent activation of the SMAD system (43) in addition 
to p38 (44), whereas increased TAK-1 expression mediates 
SMAD3 and p38 activation (45, 46). Pathways analysis 
  demonstrated a nonstochastic assembly based on cellular 
compartments of TNF-α–up-regulated elements identi-
fi  ed and confi  rmed by genomic and proteomic evaluation, 
Figure 5.  Cardiogenic priming of the endoderm by TNF-𝗂 requires 
p38 signaling. (A–D) LTQ-FT shotgun tandem mass spectrum of selected 
growth factors including IGF-1, CSF-1, BMP-1, and tissue inhibitor of 
metalloprotease-1. (E) TGF-β1 and BMP4 were up-regulated by twofold 
as determined by ELISA-based quantifi  cation. (F) Expression profi  ling of 
endodermal mRNA before and after TNF-α treatment revealed up-regulation 
of TAK-1 and TACE (Adam17) by 1.5- and 2-fold, respectively. (G) Factors 
identifi  ed by proteomic and genomic analysis integrate to highlight p38 
as a central component in the signaling network established after TNF-α 
priming of the endoderm. Expression of each node presented in this 
  interactome was confi  rmed by gene chip and tandem MS-MS dissection. 
(H) Pharmacological inhibition of p38 MAPK using SB203580 (5 μM) 
blunted the procardiogenic effect of TNF-α on embryoid bodies. (I) TGF-β 
secretion promoted by TNF-α was seen in both the embryoid body and 
the isolated ventral endoderm. Antagonism of p38 with SB203580 or 
inhibition of protein synthesis using the ribosomal inhibitor, puromycin, 
abrogated TNF-α enhancement of TGF-β production. * and ** indicate 
P < 0.05 with respect to untreated and TNF-α–treated embryoid bodies 
or endoderm, respectively.412  CARDIOPOIESIS FOR TUMOR-FREE REPAIR | Behfar et al.
highlighting p38 as an integral node of intracellular signaling 
induced by cytokine stimulation of the endoderm (Fig. 5 G). 
The central role of the mitogen-activated protein kinase 
(MAPK) p38 was confi  rmed as application of the p38 anta-
gonist SB203580 to embryoid bodies blunted TNF-α action 
(Fig. 5 H). As pathway analysis revealed TGF-β as a node 
  directly downstream of p38, ELISA evaluation of TGF-β 
  secretion was made after p38 inhibition with SB203580 and 
protein synthesis inhibition with the ribosomal antagonist 
puromycin. Direct application of SB203580 to day 4 embry-
oid bodies or isolated visceral endoderm-like cells eliminated 
TNF-α up-regulation of TGF-β secretion (Fig. 5 I). 
  Furthermore, puromycin treatment of isolated endoderm 
  inhibited the TNF-α–dependent boost in TGF-β secretion, 
indicating induction of protein synthesis. Thus, subtractive 
genomic and proteomic profi  ling of the endoderm before 
and after TNF-α stimulation identifi  es secreted endoderm-
derived cardiotrophic factors and reveals p38 as an intracellular 
mediator of TNF-α cardiogenic priming.
Synergy of endoderm-derived cardiotrophs achieves 
cardiopoietic programming
The cardiogenic aptitude of individual candidates identifi  ed 
within the TNF-α–primed endodermal secretome was tested 
on embryonic stem cells in monolayer and found to increase 
the expression of early cardiac transcription factors Nkx2.5 
and MEF-2C localized to the cytosol (Fig. 6 A). Induction 
with single recombinant factors, e.g., BMP-2 or -4, TGF-β1, 
IGF-1 or -2, and FGF-2 or -4, was, however, not suffi   cient 
to mediate nuclear import of cardiac transcription factors in 
diff  erentiating stem cells, a critical step for defi  nitive engage-
ment into the cardiac program (Fig. 6 A; reference 47). Rather, 
the synergy of factors (TGF-β1, BMP-2 and -4, activin-A, 
VEGF-A, IL-6, FGF-2 and -4, IGF-1 and -2, and EGF) identi-
fi  ed in the secretome, used as a recombinant cocktail regimen, 
induced nuclear translocation of Nkx2.5 by day 2, and of 
later cardiac transcription factors MEF-2C and GATA4 by 
day 4, indicative of defi  nitive commitment to cardiac dif-
ferentiation (Fig. 6 B). In this way, the cardiogenic cocktail 
demonstrated a capacity to recruit from embryonic stem cells 
a monolayer of cells en route to cardiac maturation. This 
intermediate cell phenotype—termed cardiopoietic progeni-
tor cells—completed the cardiac diff  erentiation program by 
day 7, demonstrating defi   nitive expression of myofi  brillar 
proteins (α-actinin) and sarcomeric organization (Fig. 6 B). 
Specifi  cally, when day 4 cardiopoietic stem cells at 10,000 
cells/ml were continuously cultured in the presence of the 
cardiogenic cocktail, sarcomeric diff  erentiation was achieved 
by day 7 in ≥10% of cells, day 9 in ≥30% of cells, and day 
12 in ≥65% of cells in culture (Fig. 7, A–C). Removal of 
the cardiogenic cocktail after 4 d of recombinant stimulation 
resulted in continued engagement of cardiopoietic cells in 
the cell cycle dividing every 36 h without diff  erentiation into 
cardiomyocytes by day 9 (≤5% of cells), and withdrawal from 
cell cycle upon confl  uence (Fig. 7 D). Electron microscopy 
further established the transitional state of cardiopoietic cells 
relinquishing a phenotype of high nucleus-to-cytosol ratio 
typical of embryonic stem cells (48), while acquiring a pro-
gressively mature cardiac structure (Fig. 7 E). Thus, the iden-
tifi  ed cardiopoietic cell population demonstrated maintained 
mitotic activity, a remnant property of the embryonic source, 
and reproducibly acquired contact inhibition with execution 
Figure 6.  Synergy of recombinant secretome components drives 
cardiogenesis of embryonic stem cells in monolayer, revealing a 
cardiopoietic population. (A) Untreated embryonic stem cells (D0, row 1) 
or cells treated for 2 d (D2, row 2) or 8 d (D8, row 3) with individual 
  components (i.e., BMP-4, FGF-2, and TGF-β1) did not demonstrate cardio-
genic specifi  cation as expression of cardiac transcription factors (Nkx2.5, 
columns 1–3; MEF-2C, column 4; GATA-4, column 5) was limited to the 
cytosol at D2 and diminished in expression by D8. (B) Combinatorial 
  stimulation with identifi  ed secretome components resulted by day 2 in 
nuclear translocation of Nkx2.5 with strong cytosolic expression of MEF-2C 
(D2, row 1), followed by recruitment of the cardiopoietic phenotype with 
nuclear translocation of Nkx2.5, MEF-2C, and GATA-4 (D4, row 2) to yield 
cardiomyocytes with completed sarcomerogenesis by day 7 demonstrated 
by α-actinin (D7, row 3). Bars: (A) 20 μm; (B) 15 μm.JEM VOL. 204, February 19, 2007  413
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of the cardiac program under the combinatorial guidance of 
the cardiogenic cocktail composed of factors identifi  ed in the 
TNF-α–primed endodermal secretome.
Cardiopoietic cells discard markers of oncogenesis 
with loss of pluripotency
Genomic expression profi  ling demonstrated progressive loss 
of pluripotent traits associated with cardiac specifi  cation of 
embryonic stem cells (Fig. 7 F). Dissection of the cardiopoi-
etic transcriptome revealed down-regulation in markers of 
pluripotency (Oct4; reference 27) and oncogenicity (MYC 
and DEK; reference 49) along with activation of cardiogenic 
pathways (MEF-2C, Nkx2.5, GATA4, and Tbx2), preced-
ing expression of the excitation-contraction machinery 
(L-type Ca2+ channel, MLC2v) typical of the cardiac lineage 
(Fig. 7 F). Diff  erentiation of embryonic stem cells untreated 
Figure 7.  Cardiopoietic cells demonstrate loss of oncogenic and 
pluripotent markers. (A–D) MEF-2C (green), α-actinin (red), and DAPI (blue) 
staining revealed cardiopoietic cells with nuclear translocation of MEF-2C 
without sarcomeric expression, spontaneously differentiating into cardio-
myocytes by day 7 (D7) of cocktail treatment (A). Cardiopoietic cells plated 
at 10,000 cells/ml (B, top), when placed in medium containing cocktail 
components ((+) Cocktail), differentiated into cardiomyoctes with ≥10% 
of cells α-actinin positive by day 7 (A), ≥30% of cells positive by day 9 
(B, bottom), and ≥65% of cells positive by day 12 (C) of stimulation. Without 
cocktail stimulation, cardiopoietic cells continued to proliferate without 
differentiation when placed in a low serum medium devoid of cocktail 
components ((−) Cocktail, D). In this condition, spontaneous differentia-
tion into cardiomyocytes was observed in ≤1% of cells by day 7 (D7, D top) 
and ≤5% of cells by day 9 (D9, D bottom). (E) On scanning electron 
microscopy, the intermediate phenotype of cardiopoietic stem cells (CP) 
contrasts from that of embryonic stem cells (ES) with high nucleus-
to-cytosol ratio, and from that of rod-shaped mature cardiomyocytes 
(CM). (F) Transcriptome profi  ling of embryonic stem cells (ES), cardiopoi-
etic stem cells (CP), and cardiomyocytes (CM; left) reveals that combina-
torial priming induces a switch from a gene expression profi  le of 
pluripotency (ES) to cardiopoiesis (CP) and cardiogenesis (CP and CM) 
before cardiomyocyte maturation and excitation-contraction coupling 
(CM). −, background expression; +, defi  nitive expression used as 
baseline; ++, ≥2-fold increase in expression. Bars: (A; also applies to C) 
5 μm; (D; also applies to B) 50 μm; (E, CP) 5 μm; (E, ES) 10 μm; and 
(E, CM) 2 μm.414  CARDIOPOIESIS FOR TUMOR-FREE REPAIR | Behfar et al.
or treated with single factors from the cardiogenic cock-
tail yielded three germinal layer embryoid bodies (Fig. 8, 
A and B), refl  ecting a maintained pluripotency. In contrast, 
day 4–recruited cardiopoietic cells no longer produced 
trigerminal layer embryoid bodies and instead formed beat-
ing cardiospheres, demonstrating commitment to the car-
diac program (Fig. 8 C). Dissociation of cardiospheres 
released cells with hallmark features of cardiomyocytes, in-
cluding action potential activity (Fig. 8 D), ion current pro-
fi  les (Fig. 8 E), rhythmic calcium transients (Fig. 8 F), and 
sarcomeric organization (Fig. 8 G). Thus, derived cardiopoi-
etic cells exchange the pluripotent and oncogenic molecu-
lar profi  le of embryonic stem cells for defi  nitive commitment 
to cardiac lineage.
Cardiopoietic cell therapy offers safe myocardial repair
The therapeutic usefulness of derived cardiopoietic cells was 
demonstrated in vivo after echocardiography-guided myo-
cardial transplantation. As seen with embryonic stem cell 
transplantation (Fig. 1, A–C), cardiopoietic cells proliferated 
and generated cardiomyocytes in the host myocardium (Fig. 9, 
A and B). However, the load yielding tumor-free outcome 
exceeded that of the embryonic source (Fig. 9 C). Delivery 
of cardiopoietic cells at ≥3 × 106 per heart produced no in-
cidence of tumors, in contrast to a  70% teratoma outcome 
that resulted from implantation of an equivalent embryonic 
stem cell load (Fig. 9 C). Cardiopoietic cells tripled the area 
of engraftment maximally attainable from embryonic stem 
cell transplantation without resultant electrical ectopy or dis-
ruption of myocardial architecture and function (Fig. 9, D 
and E). In a chronic model of myocardial infarction with 
  individual animals serving as their own control, delivery of 
cardiopoietic cells 8 wk after ligation of the left anterior de-
scending artery resulted in improved anterior wall motion, as 
detected on short axis (Fig. 9 F) and M-mode (Fig. 9 G) 
echocardiographic evaluation. Echocardiography of the in-
traventricular area before and after cardiopoietic cell trans-
plantation revealed on average a 30-mm2 decrease in the 
circumferential area during systole 2 mo after transplantation 
(Fig. 9 H), improving fractional heart output by 35% (Fig. 9 I). 
On histopathological examination, infarcted hearts treated 
with cardiopoietic cells (105 mg/heart tissue) revealed that 
engrafted cells had advanced into the cardiac program ex-
pressing CFP under control of the cardiac-specifi  c  actin 
  promoter (Fig. 10 A). Cardiopoietic cell–derived cardiomyo-
cytes exhibited distinct sarcomeric striation determined by 
Figure 8.  Cardiopoietic stem cells are confined to the 
cardiac program. (A) Hanging drop differentiation of embryonic 
stem cells resulted in differentiation of cells into all three germinal layers. 
(B) Treatment of embryonic stem cells with a single component (e.g., TGF-β1) 
of the cardiogenic cocktail increases stem cell aptitude for cardiogenesis—
demonstrated by increased beating area—but still results in trigerminal 
embryoid body formation indicating maintained pluripotency. (C) Differ-
entiation of cardiopoietic cells generated cardiospheres demonstrating 
defi  nitive propensity toward cardiogenesis. (D–G) Isolation of cells from 
cardiopoietic cell–generated cardiospheres yielded functional cardiomyo-
cytes demonstrating action potential (E), ion current activity (F), and 
  calcium transients (G) along with organized sarcomerogenesis recapitulat-
ing myocyte structure on confocal and transmission electron microscopy 
(G, inset). Bars: (A–C) 500 μm; (F) 3 s; (G) 20 μm; (G, inset) 1 μm.JEM VOL. 204, February 19, 2007  415
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α-actinin staining and populated periinfarct regions (Fig. 10, 
A and B). Furthermore, Ki67, a nuclear protein expressed by 
proliferating cells in all phases of cell cycle (50), colocalized 
with DAPI-stained nuclei of CFP-expressing cardiopoietic 
cell–derived cardiomyocytes, indicating the continued ability 
of engrafted cells to divide (Fig. 10, A and B). Thus, program-
ming of embryonic stem cells pretransplantation to generate 
the cardiac predetermined cardiopoietic cell type translated 
into safe tumor-free infarct repair.
DISCUSSION
Embryonic stem cells, although recognized for their potential 
in tissue repair, harbor the threat for neoplastic transforma-
tion because of an inherent risk for unguided diff  erentiation, 
preventing translation of embryonic stem cell therapy into 
practice. A strategy to overcome this limitation was here 
developed with the discovery that the reprogramming 
  cytokine TNF-α promotes cardiogenic specifi  cation of pluri-
potent embryonic stem cells. This previously unrecognized 
Figure 9.  Cardiopoietic programming of embryonic stem cells 
eliminates tumorigenic risk in therapy. (A and B) Delivery of derived 
cardiopoietic cells (CP) at 3 × 106/heart resulted in proper implantation 
and cardiac differentiation. (C and D) In contrast to embryonic stem cells 
(ES), treatment with cardiopoietic cells (CP) was not associated with 
tumor formation and led to a threefold increase in engraftment area. 
(E) Synchronous cardiac function monitored by multilead electrocardio-
graphy demonstrated no evidence for ectopy after delivery of cardiopoietic 
cells. I, II, III, AVF, and AVL indicate lead placement on electrocardiogram. 
(F and G) Echocardiographic evaluation of intraventricular area before and 
after cardiopoietic cell transplantation in myocardial infarction shows 
reanimation of the akinetic anterior LV wall on short axis and improved 
fractional shortening demonstrated by two-dimensional M-mode 
echocardiography during the 2-mo follow-up period. (H) In comparison to 
hearts before treatment, a 10-mm2 and 30-mm2 decrease in circumferential 
area during systole was observed on 1- and 2-mo follow-up echocardio-
graphy, respectively, resulting in a 35% increase in fractional output 2 mo 
after treatment (I). Bars: (A) 2 mm; (B) 50 μm; (B, inset) 10 μm.416  CARDIOPOIESIS FOR TUMOR-FREE REPAIR | Behfar et al.
function of the stress cytokine was demonstrated in vivo 
through cardiac-restricted transgenic overexpression of TNF-
α, resulting in augmented cardiogenic competence of the 
host heart and safe incorporation of transplanted stem cells. 
Molecular dissection of the procardiogenic action of TNF-α 
in vitro resolved the identity of cardioinductive signals, 
which when applied to embryonic stem cells recruited  cardiac 
predetermined progenitors, termed cardiopoietic progenitor 
cells. Use of cardiopoietic stem cells eliminated reliance on 
host signaling for diff  erentiation, averting the malignant risk 
of pluripotency and achieving a critical step in the translation 
of stem cells into therapy.
Transplantation of embryonic stem cells outside of the 
embryonic environment is disruptive to the normal diff  eren-
tiation program (51, 52). Although the host heart, through 
paracrine release of cardiotrophic factors, can guide stem 
cell toward cardiogenic diff  erentiation (34, 53, 54), the capa-
city of the foster milieu to secure stem cell specifi  cation and 
mimic embryonic conditions is fi  nite (24, 26), with uncon-
trolled growth resulting from increased stem cell loads. This 
indicates that noncardiogenic signaling within a pluripotent 
stem cell population (55) can overcome the limited cardio-
instructive signaling of the host heart (34, 56). The result-
ing teratoma emanating from an otherwise nontumor-prone 
myocardium contained a multiplicity of tissue types repre-
sentative of all three germinal layers, confi  rming their stem 
cell origin (12) and revealing that environmental cues play 
a critical role in aff  ecting stem cell behavior (57, 58). Tu-
morigenic outcome was precipitated by disrupting the capa-
city of stem cells to recognize paracrine cardiogenic signals, 
highlighting the importance of intact TGF-β superfamily 
signaling in cardiac specifi  cation (59). Conversely, enrich-
ing the cardiogenic capacity of the host microenvironment 
through cardiac-specifi  c TNF-α expression and up-regula-
tion of TGF-β family members prevented aberrant growth 
patterns. This indicates successful competition with non-
cardiogenic signals that are innate to embryonic stem cells, 
providing the necessary cues for cardiogenic specifi  cation. 
This fi  nding is in line with works that implicate up-regula-
tion of TNF-α and TGF-β as components of the myocardial 
stress response (36, 60, 61), contributing to the observation 
that transplantation of stem cells into diseased myocardium 
results in incorporation without tumor formation (18, 20, 62). 
Collectively, these fi  ndings underscore the importance of 
cross-talk between stem cells and the host environment in 
determining cell fate after transplantation and provide evi-
dence that manipulation of this interaction can achieve the 
desired outcome.
Although cardiac-restricted overexpression of TNF-α 
was effi   cacious in driving stem cell diff  erentiation in vivo, 
the feasibility of translating such transgenic approach into 
clinical practice remains uncertain. Moreover, the unpre-
dictable nature of the heart microenvironment in the setting 
of disease (63, 64), including variable up-regulation of cy-
tokine and growth factors after myocardial injury (65, 66), 
may not be reliable in counteracting noncardiogenic signal-
ing in diff  erentiating embryonic stem cells to ensure safety. 
Recapitulation of the procardiogenic action of TNF-α in 
vitro using the embryoid body model allowed dissection of 
the mechanism of cytokine action providing a paradigm by 
which to relinquish the noncardiogenic potential of embry-
onic stem cells and bypass the reliance on the cardiogenic 
competence of host myocardium. By targeting the endo-
derm, TNF-α activated the TAK1/p38 pathway as in the 
injured heart (61), promoting cardiogenesis via increased 
secretion of endodermal cardiotrophic factors. Although 
coculture of embryonic stem cells with the endoderm can 
guide cardiogenesis (67), the present study reveals the iden-
tity of secreted proteins through subtractive proteomic anal-
ysis of the endodermal secretome. Identifi  ed proteins within 
the primed secretome clustered into networks downstream 
of TNF-α and included potent cardiogenic factors, such as 
members of the TGF-β and FGF families (15, 68) whose 
combined application secured commitment to the cardiac 
program, recapitulating the infl  uence of the natural em-
bryonic milieu. As individual components of the derived 
cardiogenic cocktail enhance cardiac specifi  cation in vitro 
(34, 69) or in vivo (20), their combinatorial use achieved guided 
Figure 10.  Cardiopoietic progenitor cells maintain cell cycle activity 
after engraftment into the infarcted heart. (A) Histopathological 
examination of treated infarcted hearts revealed cardiopoietic cell–  derived 
cardiomyocytes incorporated into host myocardium around the infarct 
region. Low magnifi  cation confocal microscopy revealed large numbers 
of Ki67-expressing cardiopoietic cell-derived myocytes surrounding the 
infarcted region. While high magnifi  cation confocal evaluation demon-
strates CFP positive cells with organized sarcomeres aligned with host 
myocardium (A, right). (B) Ki67-expressing cells on high magnifi  cation 
confocal microscopy were CFP positive, indicating cardiopoietic cells 
as their source. Bar: (A, left) 50 μm; (A, right) 10 μm; (B, left) 15 μm; 
(B, right) 20 μm.JEM VOL. 204, February 19, 2007  417
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cardiogenesis of embryonic stem cells in a monolayer allow-
ing profi  ling of cardiopoiesis. This approach enabled cap-
ture of cardiopoietic progenitor cells with phenotypic and 
genotypic features that demonstrate diminished tendency 
for unguided diff  erentiation and loss of pluripotent and on-
cogenic markers characteristic of undiff  erentiated stem cells 
(55), with translocation of cardiac transcription factors into 
the nucleus securing cardiac specifi  cation. Untreated embry-
onic stem cells demonstrate their pluripotency by forming 
three-layer embryoid bodies (48, 70). Treatment of em-
bryonic stem cells with single cardiogenic agents, although 
promoting cardiomyocyte content, did not eliminate triger-
minal diff  erentiation. In contrast, recruitment of cardiopoi-
etic cells through application of the cardiogenic cocktail on 
a monolayer of embryonic stem cells eliminated pluripotent 
propensity, generating cardiospheres indicative of defi  nitive 
commitment to the cardiac program.
Having secured cardiogenic specifi  cation, cardiopoietic 
cells provided a safe source for cell therapy. With demon-
strated survivorship and completion of the cardiac program 
upon transplantation, along with sarcomeric alignment and 
electrical coupling within the host myocardium, this cell type 
fulfi  lled established criteria for implantation (24, 71). Cardio-
poietic cells averted tumor formation on engraftment into 
healthy hearts at doses that carry high risk for tumorigenesis 
with embryonic stem cells. Further, cardiopoietic cells main-
tained a capacity to proliferate within scar tissue, leading to 
functional recovery after engraftment into infarcted hearts. 
This is the fi  rst example where delivery of embryonic-  derived 
cardiac progenitors achieved proper myocardial integration 
without risk for unguided growth. This work thus demon-
strates that use of cardiopoietic cells eliminates reliance on 
host heart signaling for diff  erentiation, a limitation that has 
precluded pluripotent embryonic stem cells as a safe thera-
peutic option. Honing cellular plasticity to nullify malignant 
risk, therefore, achieves a critical step in translation of stem 
cells into therapy.
MATERIALS AND METHODS
Protocols were approved by Mayo Clinic Institutional Animal Care and 
Use Committee.
Embryonic stem cell–based cardiopoiesis. Murine embryonic stem 
cells were diff   erentiated into embryoid bodies using the hanging-drop 
method, with cardiac diff   erentiation monitored by epifl  uorescence  us-
ing α-actinin antibody (1:1,000) and live microscopy (34, 48). RNA was 
processed by quantitative RT-PCR using the Light Cycler (Roche) and 
QuantiTect SYBR Green kit (QIAGEN) to quantify Nkx2.5 (forward, 
reverse primers: 5′-T  G  C  A  G  A  A  G  G  C  A  G  T  G  G  A  G  C  T  G  G  A  C  A  A  G  C  C  -3′ 
and 5′-T  T  G  C  A  C  T  T  G  T  A  G  C  G  A  C  G  G  T  T  C  T  G  G  A  A  C  C  A  -3′), MEF-2C 
(5′-A  G  A  T  A  C  C  C  A  C  A  A  C  A  C  A  C  C  A  C  G  C  G  C  C  -3′ and 5′-A  T  C  C  T  T  C  A  G-
A  G  A  C  T  C  G  C  A  T  G  C  G  C  T  T  -3′), GATA-4 (5′-G  G  A  A  T  T  C  A  A  G  A  T  G  A  A  C-
G  G  C  A  T  C  A  A  C  -3′ and 5′-T  G  A  A  T  T  C  T  C  A  A  C  C  T  G  C  T  G  G  C  G  T  C  T  T  A  G  A  -3′), 
and β-MHC (5′-GCCAAAACACCAACCTGTCCAAGTTC-3 and 5′-C  T  G-
C  T  G  G  A  G  A  G  G  T  T  A  T  T  C  C  T  C  G  -3′) mRNA expression normalized to 
β-tubulin. From day 7 embryoid bodies, cardiopoietic progenitor cells were 
isolated by Percoll purifi  cation and visualized through laser confocal examination 
using MEF-2C (1:400; Cell Signaling Technologies), Nkx2.5 (1:300; Santa 
Cruz Biotechnology, Inc.), GATA-4 (1:300, Santa Cruz Biotechnology; Inc.), 
and α-actinin (1:1,000; Sigma-Aldrich). In a subset of experiments, the 
  endodermal layer was eliminated from embryoid bodies through generation 
of hanging drops in the presence of recombinant leukemia inhibitory factor 
(10 U/μl) once diff  erentiation has been initiated (38). Isolated visceral 
  endoderm-like cells were derived from an F9 cell population (American Type 
Culture Collection) with retinoic acid (1 μM), dibutynyl cAMP (0.5 mM), 
and theophylline (0.5 mM), with phenotype confi  rmed through comparison 
with END-2 cells (67). Conditioned medium obtained after 24 h of culture 
was used for dissection of procardiogenic signaling by proteomic analysis. 
To stimulate cardiopoiesis of embryonic stem cells cultured in monolayer at 
100 cells/cm2, cells were stimulated with recombinant TGF-β1 (2.5 ng/ml), 
BMP-2 and -4 (5 ng/ml), activin-A (5 ng/ml), FGF-2 and -4 (10 ng/ml), 
IL-6 (100 ng/ml), IGF-1 and -2 (50 ng/ml), VEGF-A (10 ng/ml), and EGF 
(2.5 ng/ml) either in singular or combinatorial fashion with cellular response 
monitored by confocal microscopy. When recruited from a monolayer of 
embryonic stem cells, the cardiopoietic population was enriched using a dual 
interface Percoll gradient to separate sarcomere-rich high density cardio-
myocytes (34) from the lower density sarcomere-poor cardiopoietic phenotype. 
Cardiopoietic cell proliferation and purity was assessed by ArrayScan multi-
channel fl  uorescence automated microscopy (Cellomics) using MEF-2C 
and α-actinin antibodies, along with DAPI nuclear staining. Cell morpho-
logy was resolved by fi  eld emission scanning or transmission electron micro-
scopy. Action potentials and voltage–current relationships were acquired by 
patch-clamp electrophysiology. Calcium dynamics were tracked in Fluo 
4-AM–loaded cells using laser confocal line scanning (48).
Transgenic mice. Enrichment of the myocardium with TNF-α was 
  induced by cardiac-restricted overexpression of this cytokine using the 
α-myosin heavy chain promoter linked to the TNF-α transgene as described 
(72). Wild-type females were bred with transgenic males, and resultant 
heterozygous transgenic off  spring (TNF-α–TG) identifi  ed by tail-cut PCR 
were compared with wild-type littermates (73).
Genomics. Total RNA was isolated using the Micro-to-Midi isolation 
kit (Invitrogen) and subjected to comparative gene expression profi  ling by 
labeled cRNA hybridization to the mouse genome 430 2.0 microarray 
(Aff  ymetrix). Data acquired using the GeneChip Scanner 3000 was analyzed 
with the Genespring GX 7.3 microarray data software bioinformatics suite 
(Agilent Technologies), restricting the derived gene list to identify diff  eren-
tially expressed genes defi  ned by a >1.5-fold diff  erence and P < 0.05. Data 
population sets were normalized to the undiff  erentiated phenotype and qual-
ity fi  ltered to eliminate background noise before hierarchical clustering (74). 
The dataset is available as series GSE6689 at National Center for Biotechnol-
ogy Information (National Center for Biotechnology Information) on Gene 
Expression Omnibus (GEO) website.
Proteomics. Endodermal cells were cultured with serum-free Glasgow 
modifi  ed Eagle’s medium. Derived conditioned medium was centrifuged 
and fi  ltered with protein quantifi  ed, concentrated (Amicon Ultra 5 kD cut-
off  ), and requantifi  ed for volumetric normalization. The protein equivalent 
of 5 ml conditioned medium was resuspended in isoelectric focusing (IEF) 
buff  er containing urea (7 M), thiourea (2 M), CHAPS (2% wt/vol), and 
DeStreak (15 mg/ml; GE Healthcare). Proteins were resolved in the fi  rst di-
mension using immobilized pH gradient IEF strips (Bio-Rad Laboratories) 
at pH 3–10, 4–7, and 6–11, and in the second dimension by 7.5% and 15% 
SDS-PAGE. Proteins visualized by silver staining were isolated, destained, 
and trypsin digested (75) with extracted peptides subjected to high perfor-
mance liquid chromatography–electrospray ionization tandem mass spec-
trometry using a ThermoFinnigan LTQ. Alternatively, concentrated protein 
was prepared for multidimensional liquid chromatography protein analysis 
(76) by reduction, alkylation, and sequential digestion with endoprotease 
Lys-C (Sigma-Aldrich; enzyme to substrate ratio 1:125) and trypsin (Pro-
mega; enzyme to substrate ratio 1:100). Peptides were then subjected to 
strong cation exchange chromatography, and each strong cation exchange 
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  tandem mass spectrometry using a ThermoFinnigan LTQ-FT. Proteins were 
identifi  ed from tandem mass spectrometry (MS-MS) data using SEQUEST 
and Mascot search algorithms by in silico mining of the SwissProt database. 
Identifi  ed proteins were quantifi  ed with enzyme-linked immunosorbent 
  assay, and their cardiotrophic potency was evaluated. Molecules identifi  ed by 
proteomic screening were introduced to a bioinformatics model generating 
a network based on interrelationships between orthologs mined by the Inge-
nuity Pathways Analysis. A scale-free network was generated to refl  ect levels 
of subcellular compartmentalization.
Stem cell transplantation. Under isofl  urane anesthesia, echocardiography 
with a 15-MHz probe (Acuson) was used to guide myocardial delivery of 
embryonic or cardiopoietic cells engineered for in situ tracking (70). Cardiac 
performance was monitored by echocardiography in the short axis with a 
two-dimensional M-mode probing in the long axis, Doppler pulse wave 
analysis, and 12-lead electrocardiography (77, 78). Harvested heart tissue was 
fi  xed for 1 h in 3% paraformaldehyde, paraffi   n sectioned, and subjected to 
antigen retrieval using CFP antibody for cell tracking (1:500; Molecular 
Probes) in combination with α-actinin for sarcomere visualization and DAPI 
nuclear stain. Myocardial infarction was induced by coronary ligation of the 
left anterior descending artery (18).
Statistical analysis. Comparison between groups was performed using a 
standard Student’s t test of variables with 95% confi  dence intervals.
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